Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Intangibles (2016 - 2025)

Historic Intangibles for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $8.8 million.

  • China Pharma Holdings' Intangibles rose 10117.03% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 10117.03%. This contributed to the annual value of $6.7 million for FY2024, which is 10568.23% up from last year.
  • Latest data reveals that China Pharma Holdings reported Intangibles of $8.8 million as of Q3 2025, which was up 10117.03% from $6.4 million recorded in Q2 2025.
  • Over the past 5 years, China Pharma Holdings' Intangibles peaked at $8.8 million during Q3 2025, and registered a low of $106788.0 during Q3 2022.
  • Moreover, its 5-year median value for Intangibles was $4.4 million (2024), whereas its average is $3.6 million.
  • In the last 5 years, China Pharma Holdings' Intangibles soared by 273599.66% in 2021 and then crashed by 9794.85% in 2022.
  • Over the past 5 years, China Pharma Holdings' Intangibles (Quarter) stood at $147841.0 in 2021, then surged by 1122.59% to $1.8 million in 2022, then surged by 80.1% to $3.3 million in 2023, then surged by 105.68% to $6.7 million in 2024, then surged by 31.06% to $8.8 million in 2025.
  • Its Intangibles was $8.8 million in Q3 2025, compared to $6.4 million in Q2 2025 and $6.6 million in Q1 2025.